One-year follow-up of choroidal and macular thickness in acute non-treated central serous chorioretinopathy.

Autor:	Orduña-Azcona J; Ophthalmology Unit, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain., Pérez-Fernández E; Research Unit, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain., Modamio L; Ophthalmology Unit, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain., De Manuel-Triantafilo S; Ophthalmology Unit, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain., Rodríguez-Hernández CF; Ophthalmology Unit, Hospital Universitario Infanta Cristina, Parla, Spain., Gili P; Ophthalmology Unit, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain.
Jazyk:	angličtina
Zdroj:	Clinical & experimental optometry [Clin Exp Optom] 2023 Jan; Vol. 106 (1), pp. 47-55. Date of Electronic Publication: 2022 Feb 14.
DOI:	10.1080/08164622.2021.2016022
Abstrakt:	Clinical Relevance: Choroidal and macular thickness assessments are essential to understand the evolution of central serous chorioretinopathy and could help in identifying patients more prone to recurrence. Background: The aim of this work was to evaluate changes in the choroidal thickness and macular thickness in acute non-treated central serous chorioretinopathy during a one-year follow-up. Methods: A prospective longitudinal study of 38 patients with central serous chorioretinopathy and 35 healthy controls at a tertiary care facility (Fundación Alcorcón University Hospital) was conducted. Choroidal and macular thicknesses were measured using enhanced-depth-imaging optical coherence tomography and subretinal fluid resolution and best-corrected visual acuity were evaluated, at baseline and 1, 3, 6 and 12 months. Prognostic factors determining the need for treatment were evaluated. Results: Choroidal thickness decreased in eyes with central serous chorioretinopathy ( p < 0.001) but not in fellow eyes ( p = 0.24) during one-year follow-up since the acute episode. The estimated mean choroidal thickness in symptomatic eyes was 465 µm (SE: 17.18) at baseline and decreased 58.1 µm (CI 95%: 30.1-85.9) at 12 months (p < 0.001). Best-corrected visual acuity improved over time ( p = 0.037), with a decrease of logMAR 0.086 (CI95%: 0-0.172).The macular thickness changed over time ( p < 0.001), with a decrease from baseline of 124.6 µm (CI95%: 61.4-187.9). Subretinal fluid resolved in 67% (CI 95%: 51-82) of patients at 6 months. There was no significant association between baseline choroidal thickness, macular thickness, best-corrected visual acuity, age or sex and the need for treatment. Conclusions: The choroidal thickness decreased in acute central serous chorioretinopathy episodes during a one-year follow-up. Subretinal fluid persisted in less than 20% of patients at the end of the one-year follow-up. No prognostic factors determining the need for treatment were found.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu